• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Viking Therapeutics Inc.

    7/3/25 1:07:09 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VKTX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001264949
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    VIKING THERAPEUTICS, INC.
    SEC File Number
    001-37355
    Address of Issuer
    9920 Pacific Heights Blvd, Suite 350
    San Diego
    CALIFORNIA
    92121
    Phone
    (858) 704-4660
    Name of Person for Whose Account the Securities are To Be Sold
    GREG ZANTE
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    4266118428.4311230954507/03/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common07/02/2025Restricted stock vesting under a registered planIssuerCheckbox not checked426607/02/2025Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/03/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Greg Zante

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VKTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VKTX

    DatePrice TargetRatingAnalyst
    4/29/2025$104.00Overweight
    Cantor Fitzgerald
    4/8/2025$30.00Neutral
    Goldman
    2/13/2025$102.00Sector Outperform
    Scotiabank
    2/7/2025$38.00Neutral
    Citigroup
    12/2/2024Overweight
    Piper Sandler
    11/22/2024$109.00Buy
    B. Riley Securities
    11/4/2024$90.00 → $102.00Buy
    H.C. Wainwright
    9/11/2024$80.00Overweight
    JP Morgan
    More analyst ratings

    $VKTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

      VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.  VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity. The VANQUI

      6/25/25 7:03:00 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics to Participate at Upcoming Investor Conferences

      SAN DIEGO, May 28, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences.  Details of the company's participation are as follows: William Blair 45th Annual Growth Stock ConferenceDetails: Viking management will deliver a corporate presentation, and participate in a fireside chat and 1-on-1 meetingsConference Date: June 3-5, 2025Presentation T

      5/28/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate

      4/23/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Zante Greg was granted 7,667 shares and sold $118,428 worth of shares (4,266 units at $27.76), increasing direct ownership by 2% to 168,660 units (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      7/3/25 3:31:07 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Lian Brian was granted 48,333 shares and sold $747,633 worth of shares (26,889 units at $27.80), increasing direct ownership by 0.91% to 2,388,014 units (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      7/3/25 3:31:13 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Mancini Marianna sold $118,473 worth of shares (4,266 units at $27.77) and was granted 7,667 shares, increasing direct ownership by 0.91% to 377,535 units (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      7/3/25 3:30:32 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00

      4/29/25 8:13:00 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Viking Therapeutics with a new price target

      Goldman initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $30.00

      4/8/25 9:33:02 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Viking Therapeutics with a new price target

      Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00

      2/13/25 8:13:09 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Financials

    Live finance-specific insights

    See more
    • Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735Strong Quarter-End Cash Position of $852 MillionSAN DIEGO, April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate

      4/23/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

      Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time SAN DIEGO, April 16, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We

      4/16/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

      Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity UnderwayStrong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments.

      2/5/25 4:05:00 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

      SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      11/14/24 4:30:54 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

      SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      11/12/24 5:54:36 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

      SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      11/4/24 1:54:45 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

      4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)

      4/8/25 7:05:30 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Rouan Sarah Kathryn bought $29,943 worth of shares (1,240 units at $24.15) (SEC Form 4)

      4 - Viking Therapeutics, Inc. (0001607678) (Issuer)

      4/2/25 6:29:36 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VKTX
    SEC Filings

    See more
    • SEC Form 144 filed by Viking Therapeutics Inc.

      144 - Viking Therapeutics, Inc. (0001607678) (Subject)

      7/3/25 1:07:09 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viking Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Viking Therapeutics, Inc. (0001607678) (Filer)

      5/27/25 5:20:07 PM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.

      SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

      5/12/25 10:43:30 AM ET
      $VKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care